ImmuPharma plc (LON:IMM – Get Free Report)’s stock price hit a new 52-week low during trading on Thursday. The stock traded as low as GBX 3.01 and last traded at GBX 3, with a volume of 2,133,755 shares changing hands. The stock had previously closed at GBX 3.25.
ImmuPharma Stock Up 9.8%
The company’s fifty day simple moving average is GBX 3.61 and its two-hundred day simple moving average is GBX 4.66. The company has a market capitalization of £20.63 million, a price-to-earnings ratio of -3.98 and a beta of 3.02.
ImmuPharma (LON:IMM – Get Free Report) last announced its quarterly earnings results on Tuesday, September 15th. The company reported GBX (0.84) earnings per share for the quarter. ImmuPharma had a negative return on equity of 559.87% and a net margin of 3,519.56%. Equities research analysts expect that ImmuPharma plc will post -339.00 earnings per share for the current year.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Featured Articles
- Five stocks we like better than ImmuPharma
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
